Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock ModernaTX, Inc	Common Stock ATM Offering	Common Stock	Additional Paid-in Capital ModernaTX, Inc	Additional Paid-in Capital ATM Offering	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	ModernaTX, Inc	ATM Offering	Total
Beginning balance at Dec. 31, 2021			$ 6			$ 689,866		$ (308,126)			$ 381,746
Beginning balance, shares at Dec. 31, 2021			56,969,618
Issuance of common stock					$ 12,338					$ 12,338
Issuance of common stock, shares		1,795,524
Issuance of common stock upon exercise of stock options						628					628
Issuance of common stock upon exercise of stock options, shares			150,699
Vesting of restricted common stock						(581)					(581)
Vesting of restricted common stock, shares			446,141
Issuance of common stock under ESPP						632					632
Issuance of common stock under ESPP, shares			143,455
Stock-based compensation expense						24,452					24,452
Unrealized losses on marketable securities							$ (83)				(83)
Net loss								(136,639)			(136,639)
Ending balance at Dec. 31, 2022			$ 6			727,335	(83)	(444,765)			282,493
Ending balance, shares at Dec. 31, 2022			59,505,437
Issuance of common stock	$ 1			$ 22,567					$ 22,568
Issuance of common stock, shares	5,859,375
Vesting of restricted common stock						(565)					(565)
Vesting of restricted common stock, shares			605,524
Issuance of common stock under ESPP						546					546
Issuance of common stock under ESPP, shares			235,214
Stock-based compensation expense						24,341					24,341
Unrealized losses on marketable securities							357				357
Net loss								(126,612)			(126,612)
Ending balance at Dec. 31, 2023			$ 7			774,224	274	(571,377)			203,128
Ending balance, shares at Dec. 31, 2023			66,205,550
Issuance of common stock upon exercise of stock options						31					$ 31
Issuance of common stock upon exercise of stock options, shares			22,517								22,517
Vesting of restricted common stock						(186)					$ (186)
Vesting of restricted common stock, shares			411,837
Issuance of common stock under ESPP						405					405
Issuance of common stock under ESPP, shares			332,073
Stock-based compensation expense						14,609					14,609
Unrealized losses on marketable securities							(115)				(115)
Net loss								(131,668)			(131,668)
Ending balance at Dec. 31, 2024			$ 7			$ 789,083	$ 159	$ (703,045)			$ 86,204
Ending balance, shares at Dec. 31, 2024			66,971,977